View in EDS HTML Full Text PDF Full Text

Patents as a Driver of the Unprecedented Biomedical Response to COVID-19.

Saved in:
Bibliographic Details
Title: Patents as a Driver of the Unprecedented Biomedical Response to COVID-19.
Authors: Mossoff, Adam1 amossoff@gmu.edu, Adalja, Amesh2
Source: Inquiry (00469580). 9/21/2022, p1-8. 8p.
Subject Terms: *Vaccine hesitancy, *Biotechnology, *COVID-19 pandemic, Non-communicable diseases, COVID-19, Middle-income countries, COVID-19 vaccines, Pharmaceutical technology, Vaccine development, Patents, Low-income countries, Pharmaceutical industry, Personal protective equipment
Abstract: The response by the biotech and pharmaceutical sectors to the COVID-19 pandemic has been historically unprecedented. Vaccines based in cutting-edge technologies, such as the mRNA platform, were invented, tested, and distributed to patients in less than a year. Yet politicians and activists argue that patents and other intellectual property (IP) have impeded the development and distribution of these vaccines. In explaining why this is profoundly mistaken, this essay first describes the medical and economic uncertainties inherent in the production of vaccines, especially those made in response to an emerging infectious disease like COVID-19. This makes clear the unprecedented achievement in the mass production and distribution of COVID-19 vaccines in less than 1 year after the start of the COVID-19 pandemic. It then describes the current manufacturing and licensing landscape, which was created on the basis of a market infrastructure built by reliable and effective patent rights. There is now a glut in the global supply of vaccine doses—and billions more doses are still being produced. The essay concludes by identifying the non-IP causes impeding global vaccine distribution, such as lack of infrastructure in the developing world, as well as regulatory restrictions and trade barriers. Those concerned with global vaccine equity should focus on policies to resolve these real-world problems. [ABSTRACT FROM AUTHOR]
Copyright of Inquiry (00469580) is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Education Research Complete
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: ehh
DbLabel: Education Research Complete
An: 159265995
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Patents as a Driver of the Unprecedented Biomedical Response to COVID-19.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Mossoff%2C+Adam%22">Mossoff, Adam</searchLink><relatesTo>1</relatesTo><i> amossoff@gmu.edu</i><br /><searchLink fieldCode="AR" term="%22Adalja%2C+Amesh%22">Adalja, Amesh</searchLink><relatesTo>2</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Inquiry+%2800469580%29%22">Inquiry (00469580)</searchLink>. 9/21/2022, p1-8. 8p.
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: *<searchLink fieldCode="DE" term="%22Vaccine+hesitancy%22">Vaccine hesitancy</searchLink><br />*<searchLink fieldCode="DE" term="%22Biotechnology%22">Biotechnology</searchLink><br />*<searchLink fieldCode="DE" term="%22COVID-19+pandemic%22">COVID-19 pandemic</searchLink><br /><searchLink fieldCode="DE" term="%22Non-communicable+diseases%22">Non-communicable diseases</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19%22">COVID-19</searchLink><br /><searchLink fieldCode="DE" term="%22Middle-income+countries%22">Middle-income countries</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19+vaccines%22">COVID-19 vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmaceutical+technology%22">Pharmaceutical technology</searchLink><br /><searchLink fieldCode="DE" term="%22Vaccine+development%22">Vaccine development</searchLink><br /><searchLink fieldCode="DE" term="%22Patents%22">Patents</searchLink><br /><searchLink fieldCode="DE" term="%22Low-income+countries%22">Low-income countries</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmaceutical+industry%22">Pharmaceutical industry</searchLink><br /><searchLink fieldCode="DE" term="%22Personal+protective+equipment%22">Personal protective equipment</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The response by the biotech and pharmaceutical sectors to the COVID-19 pandemic has been historically unprecedented. Vaccines based in cutting-edge technologies, such as the mRNA platform, were invented, tested, and distributed to patients in less than a year. Yet politicians and activists argue that patents and other intellectual property (IP) have impeded the development and distribution of these vaccines. In explaining why this is profoundly mistaken, this essay first describes the medical and economic uncertainties inherent in the production of vaccines, especially those made in response to an emerging infectious disease like COVID-19. This makes clear the unprecedented achievement in the mass production and distribution of COVID-19 vaccines in less than 1 year after the start of the COVID-19 pandemic. It then describes the current manufacturing and licensing landscape, which was created on the basis of a market infrastructure built by reliable and effective patent rights. There is now a glut in the global supply of vaccine doses—and billions more doses are still being produced. The essay concludes by identifying the non-IP causes impeding global vaccine distribution, such as lack of infrastructure in the developing world, as well as regulatory restrictions and trade barriers. Those concerned with global vaccine equity should focus on policies to resolve these real-world problems. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Inquiry (00469580) is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=ehh&AN=159265995
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/00469580221124819
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 1
    Subjects:
      – SubjectFull: Vaccine hesitancy
        Type: general
      – SubjectFull: Biotechnology
        Type: general
      – SubjectFull: COVID-19 pandemic
        Type: general
      – SubjectFull: Non-communicable diseases
        Type: general
      – SubjectFull: COVID-19
        Type: general
      – SubjectFull: Middle-income countries
        Type: general
      – SubjectFull: COVID-19 vaccines
        Type: general
      – SubjectFull: Pharmaceutical technology
        Type: general
      – SubjectFull: Vaccine development
        Type: general
      – SubjectFull: Patents
        Type: general
      – SubjectFull: Low-income countries
        Type: general
      – SubjectFull: Pharmaceutical industry
        Type: general
      – SubjectFull: Personal protective equipment
        Type: general
    Titles:
      – TitleFull: Patents as a Driver of the Unprecedented Biomedical Response to COVID-19.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mossoff, Adam
      – PersonEntity:
          Name:
            NameFull: Adalja, Amesh
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 09
              Text: 9/21/2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 00469580
          Titles:
            – TitleFull: Inquiry (00469580)
              Type: main
ResultId 1